Previous Close | 196.37 |
Open | 197.25 |
Bid | 197.00 x 1000 |
Ask | 198.00 x 900 |
Day's Range | 196.23 - 197.97 |
52 Week Range | 135.85 - 197.98 |
Volume | |
Avg. Volume | 5,461,259 |
Market Cap | 348.94B |
Beta (5Y Monthly) | 0.62 |
PE Ratio (TTM) | 66.29 |
EPS (TTM) | 2.98 |
Earnings Date | Oct 25, 2024 - Oct 29, 2024 |
Forward Dividend & Yield | 6.20 (3.14%) |
Ex-Dividend Date | Jul 15, 2024 |
1y Target Est | 196.64 |
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
LLY's phase III study shows that tirzepatide reduces the risk of developing type II diabetes. FDA approves PFE and MRNA's updated COVID-19 vaccine.
Now that the US government has negotiated prices for some Medicare program drugs effective in 2026, Wall Street analysts are betting on a 2027 list that will include Novo Nordisk's blockbuster Ozempic for diabetes and have a limited impact on Big Pharma. Other possible 2027 candidates include Pfizer's cancer drugs Ibrance and Xtandi, GSK's asthma and chronic obstructive pulmonary disease (COPD) treatment Trelegy Ellipta, Teva's Huntington's disease treatment Austedo and Abbvie's irritable bowel syndrome drug Linzess, according to five analysts as well as researchers and company executives.